Clinical Lymphoma Myeloma & Leukemia

Papers
(The TQCC of Clinical Lymphoma Myeloma & Leukemia is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
P-154 Multidisciplinary, Patient-Centric Bone Disease Management in Multiple Myeloma – a Single-Centre Experience40
P-112 Fall Risk Assessment and Fall Prevention in Patients With Multiple Myeloma: First Results of the MYFALL-Trial40
P-186 Identifying a New Risk-Stratification Strategy by Including Single-Cell Biomarkers in Multiple Myeloma37
P-202 Risk Factors Predicting Early Relapse for Newly Diagnosed Multiple Myeloma Patients Treated with Front-Line VRD Regimen34
P-330 Stem Cell Mobilization Strategy With Pegilgrastim for Stem Cell Transplantation for Multiple Myeloma: A Direct Cost Comparison32
P-309 Diagnostic Challenges in Systemic Amyloidosis: Exploring the Impact of Mass Spectrometry in a Middle-Income Country Cohort32
P-342 Impact of Achieving <VGPR With Dara-RVD Induction Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients31
OA-27 Para-Medullary (PMD) and Extra-Medullary (EMD) Myeloma Demonstrate Increased Copy Number Aberration, Mutational Burden, Structural Variants and Genomic Complexity Compared to Marrow-Based Myelom30
P-012 Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma29
P-068 Developing Novel DKK1-A2 CAR-T Cell Therapy for Myeloma and Other Hematologic Malignancies28
P-113 An Artificial Intelligence-Based 3D-Segmentation Assessment of Sarcopenia Utilizing Whole-Body Computed Tomography in Patients With Multiple Myeloma27
P-455 Survey of multiple myeloma (MM) patients and healthcare professionals (HCPs) on the relevance of existing health quality-of-life (QoL) questionnaires (QoLQ) to real-world QoL issues of MM patien26
P-139 Impact of melphalan staggered dosing prior to autologous hematopoietic cell transplantation for multiple myeloma patients22
P-100 Prevalence of monoclonal gammopathies in adult Uruguayan population22
MPN-153 A Phase 1b Trial of DISC-0974, an Antihemojuvelin Antibody, in Participants With Myelofibrosis and Anemia21
Management Challenges in Patients with Treatment-Free Remission of Chronic Myeloid Leukemia21
Demographic Characteristics of Hospitalized Patients With History of Multiple Myeloma in Remission: Insights From National Inpatient Sample 202121
MM-731 Prognostic Implications of Immune Paralysis in Newly Diagnosed Multiple Myeloma21
OA-38 Physical activity interventions to improve functional performance in patients with multiple myeloma21
IBCL-381 Studying the Impact of CD38 Expression on Extracellular Adenosine and Its Connection With the PD1/PDL1 Axis in Mature B-Cell Lymphoma Patients20
ABCL-440 Preliminary Safety and Efficacy Data of Combination Polatuzumab Vedotin Rituximab, Cyclophosphamide Adriamycin, Prednisone (Pola-R-CHP) in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) 19
CT-244 Updated Clinical Progress of IL-10 expressing CD19 CAR-T Cells for Treatment of Relapsed or Refractory B-Cell Hematological Malignancies at Tiny Doses19
MM-542 Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab Bortezomib, and Dexamethasone in Pati19
Frequency of Practice-Changing Findings Identified by Comprehensive Genomic Profiling in Non-Myeloid Hematologic Malignancies19
Utility of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma Patients – A Single Institution Experience From Pakistan19
MM-597 Diarrhea in Multiple Myeloma Autologous Stem Cell Transplant Recipients: Think Beyond Mucositis18
Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Sub-Analysis of Black Patients18
Therapeutic Efficacy of Acupuncture Combined With Pharmacology in Bortezomib-Induced Peripheral Neuropathy18
ALL-441 Outcome of Adult Acute Lymphoblastic Leukemia, a Single-Center Experience18
Barriers to Receiving Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Insights From a Large-Scale Multicenter Observational Study18
MPN-307 Systemic AA Amyloidosis as a Complication of Idiopathic Multicentric Castleman's Disease18
CLL-656 Multiplex ligation-dependent probe amplification (MLPA): Utility as a first line screening tool for detection of clinically relevant genomic aberrations in CLL17
CML-674 Molecular Screening of Tyrosine Kinase Inhibitor Resistance in Tunisian Patients With Chronic Myeloid Leukemia17
Evaluating the Impact of an Electronic Medical Record (EMR) Alert on Appropriate Dosing of Luspatercept in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Community Oncology Network17
Time-Dependent Transfusion Status as an Independent Predictor of Overall Survival: A Post Hoc Analysis of 3 Phase 3 Trials16
MM-645 Updated OS of Patients With AL Amyloidosis After CAEL-10116
Influence of Heart Failure Upon Incidence Rates of Pneumonia, Acute Respiratory Failure, Sepsis and Septic Shock in Patients With Polycythemia Vera16
CT-175 The Impact of Diabetes Mellitus on Hematopoietic Stem Cell Mobilization16
CML-627 Concomitant Acid-Reducing Agents With TKI Increases Time to Achieve Remission in Patients With CML: A Real-World Analysis of a US Claims Database16
Accessing BTK Inhibitors and Other Novel Therapies for Mantle Cell Lymphoma: Are We All Invited to the Party?16
Dose-Adjusted Melphalan Yields Comparable MRD-Negativity to Full-Dose Melphalan in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant16
Limited Toxicity and Impressive Outcomes of Upfront Flag-Based Induction in Newly Diagnosed Acute Myeloid Leukemia: An Indian Scenario16
Olutasidenib Demonstrates Promising Tolerability and Efficacy in IDH1-Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms16
Association Between Hemoglobin Improvement and Patient-Reported Outcomes in Patients With Myelofibrosis and Anemia: Post Hoc Pooled Analysis of Momelotinib Phase 3 Trials15
Management of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoiesis-Stimulating Agent (ESA) Treatment15
Outcomes of Bone Marrow Transplant in ESRD vs Non-ESRD Patients: A Nationwide Analysis15
Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)15
Higher Relapse Rate and Resource Utilization With Ara-C Consolidation Chemotherapy Alone Compared With Hematopoietic Cell Transplantation in First Remission in a Cohort of Younger Adults With Acute My15
Epidemiological Profile and Outcomes of Patients Admitted to the Intensive Care Unit at Yeolyan Hematology and Oncology Center: A Retrospective Study15
MDS-570 NPM1-Mutated Myeloid Neoplasms Irrespective of Blast Count Are Associated With Better Outcomes With Acute Myeloid Leukemia Treatment Approach15
P-383 A 16-gene signature reflecting tumor microenvironment predicts the risk of multiple myeloma patients treated by bortezomib-based therapies14
P-361 Genomic and transcriptomic landscape of hyper-APOBEC multiple myeloma14
Neurolymphomatosis: An Unusual Manifestation of Relapsed/Refractory Lymphoma14
P-278 Estimating the size of patients with relapsed/ refractory multiple myeloma treated with 1-3 and 4 or more prior lines of therapy in the United States14
P-266 Pre-clinical characterization of SAR442257, a CD38xCD28xCD3 trispecific T-cell engager in relapsed/refractory multiple myeloma14
P-200 MAP4K2 inhibition reinforces sensitivity to iberdomide in RAS-mutated MM through a CRBN-independent mechanism14
OA-22 TiMMing: developing an innovative suite of bioinformatic tools to harmonize and track the origin of copy number alterations in the evolutionary history of multiple myeloma14
IBCL-541 A Comprehensive Single-Cell Multi-Omic Analysis to Depict the Biological Heterogeneity of Follicular and Large B-Cell Lymphomas14
Editorial Board14
P-378 Longitudinal antibody and T-cell kinetics over four doses of COVID-19 vaccination and predictors of poor response in patients with multiple myeloma14
P-309 ZnDDC, a novel CELMoD-like agent binding to DDB1-CRBN complex demonstrates significant synergism with BTZ and IMiDs and overcomes IMiDs resistance in myeloma cell lines and primary samples14
Monoclonal Insulin Autoimmune Syndrome Successfully Treated With Plasma Cell Directed Therapy14
OA-08 GPRC5D-targeted CAR-T cell therapy in patients with relapsed or refractory multiple myeloma progressing after or refractory to BCMA CAR-T cell therapy: updated eesults from a phase 2 clinical tr14
Exploring Molecular Glues to Activate Proteasomes and Develop Shared and Personalized Neoantigen-Based Therapeutics in Multiple Myeloma13
Assessing the Clinical Implications and Prognostic Value of Light-Chain N-Glycosylation in 781 Multiple Myeloma Patients at Diagnosis13
Current Survival and Causes of Mortality of Myeloma Patients in Real Word Setting13
The Value of Progression-Free Survival (PFS) from the Perspectives of Patients with Multiple Myeloma (MM) and Treating Physicians: Quantitative Research Findings from Eight Countries13
CALM: A Deep Learning Time Series Model for Predicting Progression from Smoldering Multiple Myeloma Using Clinical Data13
Recent Trends in Real-World Frontline Treatment Patterns and Outcomes for Patients with Multiple Myeloma in the United States13
High-Throughput Chemical Biology Screens Unravel Precision Medicine Strategies for Multiple Myeloma13
BCMA CAR T-Cell Therapy in Newly Diagnosed Transplant-ineligible Multiple Myeloma: An Open Label, Single-arm, Phase 2 Study (CAREMM-001)13
Composition and Functional State of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment13
Quadruplet Therapy and ASCT in Multiple Myeloma: Does It Increase Toxicity?13
Outcomes of Teclistamab (Tec) Step-Up Dosing in Outpatient/Hybrid Settings Among a Large Sample of Relapsed Refractory Multiple Myeloma (RRMM) Patients Treated with Tec13
Dynamic Prediction of Progression Based on Minimal Residual Disease (MRD) in Patients with Newly Diagnosed Transplant Eligible Multiple Myeloma12
A Multistakeholder Qualitative Analysis of Barriers to Autologous Stem Cell Transplantation for Multiple Myeloma12
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study12
AVicious Cycle Between Sensory Nerve Outgrowth and Myeloma Tumor Progression in the Bone Marrow12
Health-Related Quality of Life in Indian Patients with Multiple Myeloma: A Pan-India Digital Survey-Based Assessment12
Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study12
Real-World Outcomes of SLiM-Only Multiple Myeloma: Korean Multicenter Retrospective Analysis12
Outcomes after Second Autologous Hematopoietic Cell Transplant in Patients with Relapsed Multiple Myeloma in Latin America12
Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group12
POSTER: MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia11
POSTER: ALL-020 Localized and Generalized Lymphadenopathy Referred to 3 Tertiary Pediatric Centers Over 6 Years: The Alarming Signs11
POSTER: AML-260 A Metabolically Optimized, Non-Cytotoxic Low-Dose Weekly Decitabine/Venetoclax Regimen in MDS and AML11
POSTER: HL-281 Treatment of Relapsed Hodgkin Lymphoma With Pembrolizumab as Monotherapy11
P-138 Real World Single Centre Experience On The Use of Radiotherapy In The Treatment of Patients with Multiple Myeloma11
MM-508 Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update11
POSTER: AML-112 Impact of Consolidation Chemotherapy Intensity Before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia11
POSTER: HL-603 Hodgkin Lymphoma in Tripoli University Hospital Libya11
POSTER: MPN-183 Interferon Treatment Suppresses In Vitro NETosis in Neutrophils Derived from Patients With Myeloproliferative Neoplasms11
P-314 Daratumumab for Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin G Deposits and Severe Chronic Kidney Disease11
Impact of Facility Type on Survival in Chronic Myelomonocytic Leukemia: A Propensity Score Matched, National Cancer Database Analysis11
ABCL-181 Germinal Center Double Hit Diffuse Large B-Cell Lymphoma Refractory to Chemoimmunotherapy: A Case Report11
POSTER: MDS-145 A Successful Treatment of Relapsed/Refractory MDS Patient who is Followed Under Hemodialysis11
POSTER: CT-127 Evaluation of Cytomegalovirus Infection/Disease Frequency and Risk Factors Following Allogeneic Stem Cell Transplantation: A Single Center Experience11
MCL-179 TP53 Gene Mutations in Russian Patients With Mantle Cell Lymphoma (MCL)11
POSTER: ABCL-222 Diffuse Large Cell Lymphoma of the Uterus Presented With Vaginal Bleeding: A Case Report11
POSTER: AML-331 Utility of Echocardiogram in Neutropenic Patients With Gram Positive Bacteremia – A Retrospective Study11
POSTER: TCL-196 Hepatosplenic T-Cell Lymphoma in Adolescents and Young Adults: A Case Report11
POSTER: AML-132 QuANTUM-First Trial: FLT3–Internal Tandem Duplication (FLT3-ITD)–Specific Measurable Residual Disease (MRD) Clearance Is Associated With Improved Overall Survival (OS)11
ABCL-269 Secondary Central Nervous System (CNS) Involvement in Diffuse Large B Cell Lymphoma (DLBCL): Ten-Year Outcomes From Mexico's National Cancer Institute11
CML-062 Define the Vulnerable - Social Determinants of Health Impact on Hematological Malignancies Affecting Children, Adolescents, and Young Adults: Systematic Review and Meta-Analysis11
P-020: PD1-based chimeric-switch receptor expressing NK cells recover from immune checkpoint inhibition in cancer10
P-097: A novel anti-BCMA lipid-based nanoparticle for multiple myeloma therapy10
AML-446 Time to Resolution of Myelosuppression and Associated Hospitalization in Patients With Newly-Diagnosed Acute Myeloid Leukemia (AML) Treated With Ivosidenib (IVO) + Azacitidine (AZA) Compared t10
POSTER: ABCL-142 Efficacy and Safety of Single-Agent Blinatumomab as Salvage Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia (B-ALL): Real-Life Experience10
POSTER: ALL-553 Unexplained Increase in Incidence of T-Acute Lymphoblastic Leukemia/Lymphoma in Armenia10
POSTER: TCL-154 STAT3 Mutations are Associated With Differential Treatment Responses to Methotrexate and Cyclophosphamide in T-Large Granular Lymphocyte Leukemia10
IBCL-297 Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPD) and EBV-Positive Non-Hodgkin Lymphomas (NHL)10
CT-009 Prognostic Role of Lymphocyte to Monocyte Ratio in PTS Treated With CAR-T for Aggressive Lymphoma10
POSTER: AML-369 Outpatient-Based Low-intensity Induction With Sorafenib in FLT3-ITD-Mutated Newly Diagnosed Acute Myeloid Leukemia (AML)10
MM-125 Adipose Tissue Metabolic Activity in Multiple Myeloma10
POSTER: MPN-193 Incidence of Blast Phase in Myelofibrosis According to Anemia Severity10
POSTER: MPN-498 Addition of Navitoclax to Ruxolitinib for Myelofibrosis Patients With Relapsed/Refractory Disease and Suboptimal Response to Ruxolitinib Monotherapy: REFINE Cohort 1 Dose Escalation an10
MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia10
ALL-606 A Comprehensive Retrospective Analysis of Cases from 2020-2022 in Children With Relapsed Acute Leukemia: Temporal Trends and Clinical Characteristics10
AML-013 Differences in Length of Stay Between De novo Diagnosed and Transferred Patients With Acute Myeloid Leukemia in a Community Hospital10
P-141: Prognostic impact of CD3/CD34 ratio in apheresis collection in multiple myeloma patients undergoing autologous stem cell transplant10
POSTER: CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies10
POSTER: ABCL-039 Metformin in Combination With the Standard Therapy in Patients With Diffuse Large B-Cell Lymphoma: A Randomized Phase II Clinical Trial10
Table of Contents10
Factors Influencing Physician Discretion to Administer CNS Prophylaxis in Diffuse Large B Cell Lymphoma: A Single Institution Retrospective Study10
POSTER: MDS-156 Pyrimethamine Shows Synergy and Efficacy in Combination With Venetoclax in Preclinical Models of Therapy Resistant MDS/AML10
AML-194 Second Hematological Malignancies in Survivors of Breast Cancer: An Indian Institutional Analysis9
Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma9
P-206: Antibodies to omicron variants are maintained in newly diagnosed MM patients on lenalidomide, cyclophosphamide, bortezomib and dexamethasone (RCyBorD): results from the UK RADAR/Myeloma XV Tria9
P-019: Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma patients treated with idecabtagene vicleucel (ide-ce9
Poster: MM-198 Anti-BCMA Therapy in Multiple Myeloma: A Single-Center Experience9
OAB-056: Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multipl9
P-247: Addressing the knowledge gap to optimize treatment sequencing for patients with relapsed/refractory multiple myeloma9
MM-341 Clinical Characteristics and Risk of Progression in Patients With Monoclonal Gammopathy of Uncertain Significance (MGUS): Long-Term Experience in a Single Tertiary Hospital9
AML-053 Assessment of Minimal Residual Disease in Patients With Adult Acute Myeloid Leukemia: Single Egyptian Center Experience9
POSTER: MM-638 Role of the Combination of FDG-PET plus Whole Body MRI for Staging Newly Diagnosed and Relapsed/Refractory Multiple Myeloma (MM): A Prospective Trial9
Poster: CT-132 Outcome of Sex-Mismatched Allogeneic Hemopoietic Stem Cell Transplantation from Human Leukocyte Antigen–Identical Sibling Donors in Patients With Hematologic Diseases9
Poster: CT-227 Dual CAR-Engineered NK92 Cells: An Off-the-Shelf Cell Therapy for Cancer9
MM-369 Clinical Diversity of Multiple Myeloma Over Time, From First Presentation to Diagnosis, in Kurdistan Region, Iraq9
OAB-053: Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)9
Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial9
EXABS-161-MPN Management of Pre-Fibrotic Primary Myelofibrosis9
P-212: Quantifying the average treatment effect of single vs. tandem autologous stem cell transplantation in newly diagnosed multiple myeloma using causal inference9
MDS-556 Comparison of Demographics, Disease Characteristics and Outcomes Between Black and White Patients With Myelodysplastic Syndrome: A Population-Based Study9
EXABS-134-ALL Dual CAR T-Cell for ALL9
P-100: Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma9
AML-271 Acute Stroke Secondary to Patent Foramen Ovale (PFO) in Patients With Acute Myeloid Leukemia (AML)9
MM-530 Interventions and Outcomes of Multiple Myeloma Patients Progressing after BCMA-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy8
MM-459 Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis8
MPN-469 Rusfertide (PTG-300) Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit Observed in Patients With Polycythemia Vera8
Poster: CT-195 Predictive Value of ST2, REG3a, and MAGIC Algorithm in Haploidentical Transplantation With Post-Transplant Cyclophosphamide Outcomes8
AML-327 Novel Anti–B7-H3 Blocking Antibody Enhances NK Cell–Mediated Cytotoxicity and Improves Outcomes in AML-Bearing Mice8
MPN-1333: Essential Thrombocythemia (ET) Presenting as Bilateral Adrenal Hemorrhage in an Older Adult Patient: A Rare Clinical Manifestation of a Myeloproliferative Neoplasm (MPN)8
POSTER: CT-1454 CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Aggressive B-Cell Lymphomas8
Poster: MPN-238 Single-Cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease of Megakaryocytic Progenitors and Normalization of CD4+ T Cells in Peripheral Blood8
AML-156 Early Deaths in Patients With Newly Diagnosed Acute Promyelocytic Leukemia: A Single-Center Retrospective Study From a General Hospital8
Poster: MM-474 Minimal Residual Disease Perception and Utilization in Real-World Multiple Myeloma Treatment8
Poster: ABCL-523 Immunohistochemical (IHC) Expression of Epigenetic Regulators (EZH-2 and H3K27) as well as Cell Cycle Regulators (P16, P53 and RB) in Patients Diagnosed With Primary Diffuse Large B-C8
TCL-306 Application of the Proposed Immunohistochemistry Algorithm for the Prognostication of GATA3 and TBX21 Subtypes of Peripheral T-Cell Lymphoma, Not Otherwise Specified8
ALL-031: Outcome of Adult Acute Lymphoblastic Leukemia: A Single-Center Experience8
HL-477: Who Should We Screen for Germline Cancer Predisposition in Pediatric Lymphoma?8
CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia8
EXABS-147-AML How Do We Overcome Resistance to Venetoclax8
P-001: RNA-sequencing reveals transcriptomic similarity of AL amyloidosis and MGUS aberrant plasma cells along with several potential ALA target candidate genes8
Poster: TCL-084 Subcutaneous Panniculitis-Like T-Cell Lymphoma With Co-Existing Lupus Panniculitis: A Case Report8
Poster: CLL-517 Hypertension as an Adverse Event of Ibrutinib: Does Age Matter?8
POSTER: CLL-773 Real-World Outcomes of BTK Inhibitors (BTKi) in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients With Preexisting Cardiovascular Comorbidities8
MM-1419: Pooled Incidence of Cytokine Release Syndrome in Talquetamab Therapy for Relapsed/Refractory Multiple Myeloma: A Systematic Review8
Poster: CT-329 CD19-Directed Chimeric Antigen Receptor T Cell Therapy in Waldenström Macroglobulinemia: Initial Experience in Two Clinical Trials8
POSTER: AML-481 Treatment Outcomes of All-Trans Retinoic Acid, Arsenic Trioxide, and Daunorubicin in High-Risk Pediatric Acute Promyelocytic Leukemia: A Single-Center Study From a Quaternary Care Cent7
POSTER: CML-1112 Pregnancy Outcomes in Women With Chronic Myeloid Leukemia: A Single-Center Experience From Pakistan7
POSTER: AML-983 Evaluating ChatGPT’s Responses to Commonly AskedQuestions in Allogeneic Hematopoietic Stem Cell Transplantation: A Physician-Based Assessment7
POSTER: ABCL-755 Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma (NHL)7
ORAL ABSTRACT: ALL-712 Can Chimeric Antigen Receptor T-Cell Therapy Be a Definitive Treatment for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Without Stem Cell Transplant? Long-Term 7
POSTER: CT-087 Preliminary Insights into CAR-T Therapy for Melanoma: A Systematic Review7
TCL-1382: Evaluating Mortality Trends and Disparities Related to T-Cell Lymphomas Among Adults in the United States: A Retrospective Analysis of Two Decades7
POSTER: CT-230 Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study7
EXABS-176-AML: How to Best Incorporate FLT3 Inhibitors in the Management of FLT3-Mutated AML7
ABCL-1061: Prevalence and Clinical Outcomes of Hepatitis B Virus Seropositivity in Lymphoma Patients Undergoing Rituximab-Based Therapy7
TCL-1041: Aggressive CD56-Negative T-Cell Large Granular Lymphocyte Leukemia With Liver Infiltration in a Young Adult: A Rare Case Report7
IBCL-341: Fixed-Duration Subcutaneous Mosunetuzumab in Patients With Previously Untreated High-Tumor Burden Follicular Lymphoma (FL): Interim Results From the Phase 2 MorningSun Study7
POSTER: AML-995 QuANTUM-Wild: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in FLT3-ITD–Negative Acute M7
ALL-160: A Retrospective Analysis of Molecular Markers in Patients Diagnosed With Acute Lymphoblastic Leukemia in 4 Consecutive Years—A Single-Center Experience7
CT-1329: Trends in Anemia- and Pneumonia-Related Mortality (1999–2023): A CDC WONDER Database Analysis7
POSTER: MDS-307 Acquired Platelet Dysfunction Secondary to Myelodysplastic Syndrome: Successful Resolution With Syndrome-Directed Therapy7
CT-1344: Real-World Experience With Ruxolitinib for Steroid-Refractory Acute Graft-vs-Host Disease in a Latin American Center7
POSTER: ABCL-501 Treatment of Mediastinal Gray Zone Lymphoma After Progression on First-Line Therapy Including Rituximab: Treatment With High-Dose Therapy, Nivolumab and Ipilimumab7
IBCL-1447: Outcomes of Hairy Cell Leukemia Treatment: A Single Center Experience7
POSTER: ABCL-475 5-Year Analysis of the POLARIX Study: Prolonged Follow-Up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on7
CLL-1044: Beyond the Stage: The Evolving Landscape of Cytogenetic Risk in African Americans With CLL and Its Impact on Clinical Strategies7
POSTER: AML-686 Diagnostic Yield of Bronchoscopy in Patients With Hematological Malignancies7
MCL-365: Mantle Cell Lymphoma and Cisplatin-Induced Hyponatremia: A Case Report7
MM-1377: Balancing Efficacy and Safety: Apixaban vs Rivaroxaban in Multiple Myeloma-Associated Thrombosis and Clinical Outcomes7
AML-1129: Racial and Ethnic Differences in the Outcomes of Acute Myeloid Leukemia Among Adolescent and Young Adult Patients: Insights From the SEER Database7
POSTER: MM-846 Global Disparities in Multiple Myeloma Outcomes: A World Health Organization Region-Based Analysis of Survival Proxies and Health System Indicators7
POSTER: CLL-1245 Longitudinal Single-Cell Profiling of CLL Patients Exposed to BTK and BCL2 Inhibitors7
MM-145: Clinical characteristics and molecular genetic factors in patients with extramedullar bone lesions7
POSTER: MPN-1441 Thrombosis Before Diagnosis: A 22-Year National Analysis of Missed Opportunities in Polycythemia Vera and Essential Thrombocythemia7
MDS-1306: Survival Trends and Prevalence Disparities in Refractory Anemia With Ringed Sideroblasts7
AML-1467: Adiposity-Driven Leukemogenesis: Global Trends in Acute Myeloid Leukemia Attributable to High BMI Across 204 Countries (1990–2021)7
POSTER: CT-929 Resolution of Infectious Episodes Through Surgical Interventions in Severely Neutropenic and Thrombocytopenic Patients7
MM-101: Iberdomide (IBER), Daratumumab (DARA), and Dexamethasone (DEX) (IberDd) in Transplant-Ineligible (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Results From the Phase 1/2 CC-220-MM-001 Trial7
MM-547: Role of IL10 Single-Nucleotide Variation in Multiple Myeloma7
POSTER: ABCL-361 Time-Limited Antithrombotic Prophylaxis Reduces the Risk of PICC-Related Thrombosis in Patients With Aggressive B-Cell Lymphoma Receiving DAEPOCH-R7
HL-439: Superadded HLH in a Child With Hodgkin Lymphoma and Concurrent EBV Viremia: Case Report7
AML-666: Mutational Landscape of the RTK-RAS Signaling Pathway in Acute Myeloid Leukemia: Insights From Whole-Exome Sequencing7
MPN-524: Phase 3 Study Comparing Ropeginterferon Alfa-2b With Anagrelide As Second-Line Treatment for Essential Thrombocythemia: SURPASS-ET Trial7
AML-396 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Initial Results of a Novel, Ongoing BPDCN International Registry Program6
SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia—How to Define the Treatment Value?6
POSTER: ABCL-1113 Safety and Efficacy of AZD0486, a CD19 × CD3 T-Cell Engager, in Relapsed or Refractory Diffuse Large B-Cell Lymphoma6
MM-718: Lisaftoclax (APG-2575) Combined With Novel Therapeutic Regimens in Patients With Relapsed or Refractory (R/R) Multiple Myeloma (MM) or Immunoglobulin Light-Chain (AL) Amyloidosis6
P-067 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma6
CLL-1397: Genetic and Mutational Characterization in Patients With Chronic Lymphocytic Leukemia at the Guatemalan Social Security Institute6
P-232 Comprehensive Genomic Sequencing Predicts Sub-Optimal Response to Bispecific Antibodies (BsAb) and Chimeric Antigen Receptor T Cells (CAR-T) in Multiple Myeloma (MM)6
AML-976: V-RULES: Impact of Treatment Setting on CPX-351 Safety and Effectiveness in Secondary Acute Myeloid Leukemia6
Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study6
CT-1338: Impact of Depression on In-Hospital Outcomes Among Patients Undergoing Bone Marrow Transplantation: A National Inpatient Sample Analysis6
CLL-563: Bexobrutideg (NX-5948), a Novel Bruton's Tyrosine Kinase Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Findings from6
EXABS-136-LYM: Management of Burkitt Lymphoma6
POSTER: AML-1290 Outcomes in Patients Younger Than 50 Years Old (yo) With Treatment-Naive Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated With Tagraxofusp: Subanalysis of a Phase 1/2 Tria6
MDS-304 Disparities in Myelodysplastic Syndromes Mortality Among Older Adults in the United States: A CDC WONDER Database Analysis6
Safety, Feasibility, and Efficacy of Exercise Interventions for People With Multiple Myeloma: A Systematic Review6
ALL-004 Philadelphia Chromosome-Positive T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma: A Rare Case Report6
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial6
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma6
POSTER: ABCL-167 Post-Transplant Lymphoproliferative Disorder: Key Considerations and Real-World Analysis in a University Hospital in Northeastern Brazil6
Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and/or Refractory Multiple Myeloma: A Real-World Analysis6
POSTER: CLL-950 Chronic Lymphocytic Leukemia Mortality in the US (1999–2023): A National Analysis From CDC WONDER6
OA-14 Prospective Functional Bone Disease Evaluation of Newly Diagnosed Multiple Myeloma with Combined Use of (18)F-FDG-PET/CT and Whole-Body Diffusion Weighted Magnetic Resonance6
AML-1252: Equitable Overall Survival in AML With Hypomethylating Agent and Venetoclax Despite Medically Underserved Area or Driving Distance: A Comparative Cohort Analysis Including Intensive Chemothe6
Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospec6
IBCL-783: High CR and MRD Negativity Rates With GLPG5101, a Fresh, Stem-Like, Early Memory CD19 CAR T With 7-Day Vein-to-Vein Time: Full Results From ATALANTA-1 Cohort 3 (iNHL)6
CT-696: Results of Low-Dose Cyclophosphamide in GVHD Prevention After Allo-HSCT for Acute Leukemia in Uzbekistan6
POSTER: MM-872 Racial Disparities in Clinical Outcomes Among Patients With Newly Diagnosed Multiple Myeloma in the United States: A 21-Year Comparative Analysis6
Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival6
P-430 Incidence of primary plasma cell leukemia with the new diagnostic criteria6
Recent Advances in the Use of Chimeric Antigen Receptor–Expressing T-Cell Therapies for Treatment of Multiple Myeloma6
Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis6
MPN-537: Decoding Myeloid Neoplasms: The Transformative Role of Next-Generation Sequencing in Hematology Oncology—Real-World Data From Resource-Constrained Settings6
Delphi Survey on Measurable Residual Disease in Multiple Myeloma: Prevailing Practices and the Way Forward in India6
Evaluating Response Trends of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: Analysis of Individual Patient Data From a Randomized Controlled Phase II Study to Facili6
POSTER: MM-1153 Thromboprophylaxis Using Factor Xa Inhibitors Provides Better Outcomes Than Traditional Anticoagulants in Multiple Myeloma Patients Undergoing Immunomodulatory Therapy: A Systematic Re6
Real-World Comparison of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: KMM2004 Study6
ALL-852: Retrospective Analysis of Hepatotoxicity Associated With Inotuzumab Therapy in B-Cell Acute Lymphoblastic Leukemia: Describing a New Clinical Phenomenon Called Calicheamicin Syndrome6
Practical Guidance on the Clinical Management of Belantamab Mafodotin for Patients With Relapsed/Refractory Multiple Myeloma: Recommendations From the Middle East and North Africa Expert Panel6
POSTER: AML-114 All-Trans Retinoic Acid and Arsenic Trioxide versus All-Trans Retinoic Acid and Chemotherapy in Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials6
POSTER: MCL-611 Complete Response in Heavily Pretreated Refractory Mantle Cell Lymphoma After Bendamustine and Glofitamab: A Paradigm Shift in Immunotherapy Sequencing6
EXABS-230-ABCL: Potential of AI Remote Patient Monitoring for Lymphoma6
POSTER: TCL-1001 Tumor Microenvironment Profiling in Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma Using Codex Multiplex Imaging6
MCL-1122: A SEER Study on Incidence and Survival Trends in Mantle Cell Lymphoma Involving Tonsils6
SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia6
0.10602784156799